<p><strong>Propranolol</strong>: The dose of Rizatriptan should be adjusted in propranolol-treated patients, as propranolol has been shown to increase the plasma AUC of rizatriptan by 70%&nbsp;<br />
<br />
<strong>Ergot-Containing Drugs</strong>: Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and Rizatriptan within 24 hours is contraindicated<br />
<br />
<strong>Other 5-HT1 Agonists</strong>: Because their vasospastic effects may be additive, co-administration of Rizatriptan and other 5-HT1 agonists within 24 hours of each other is contraindicated&nbsp;<br />
<br />
<strong>SSRIs /SNRIs And Serotonin Syndrome</strong>: Cases of serotonin syndrome have been reported during co-administration of triptans and selective serotonin&nbsp;reuptake&nbsp;inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)&nbsp;<br />
<br />
<strong>Monoamine Oxidase Inhibitors</strong>: Rizatriptan is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. A specific MAO-A inhibitor increased the systemic exposure of rizatriptan and its metabolite.</p>